Bruker has announced its new MALDI PharmaPulse 2.0 solution (MPP 2.0), which significantly enhances the automation capabilities of the rapifleX MALDI mass spectrometer, with its proprietary scanning 10 kHz solid-state laser technology, for label-free, uHTS assays in pharmaceutical drug discovery. MPP 2.0 enables pharma scientists to automate MALDI methods development to screen millions of compound chemical libraries using 384, 1536, 3072, or 6144-well microtiter format MALDI sample plates. The new MALDI PharmaPulse 2.0 solution can measure up to 10 different samples per second, a 100- to 1000-fold increase in speed and throughput for mass spectrometry-based, label-free screening. The MPP 2.0 solution is compatible with the latest 1536 simultaneous liquid spotters, and fully integrated automation solutions for uHTS,

The MPP 2.0 solution incorporates an assay development module and a screening module. The assay development module harnesses the speed of the rapifleX MALDI PharmaPulse in a multi-dimensional approach, performing serial dilutions, mixing different buffer concentrations, and other assay components, and uses a proprietary algorithm to identify the optimum assay conditions. The screening module synchronizes with external lab automation protocols to seamlessly integrate with the symphony of robotics required to perform fully automatic, ultra-high speed screening campaigns. The new MALDI PharmaPulse 2.0 user interface was developed in cooperation with scientists for seamless integration of mass spectrometry with uHTS robotics routinely used in the pharmaceutical industry. The unambiguous nature of direct mass measurement for primary screens, the enormous cost savings with label-free detection, and just nanoliter sample consumption, coupled to smart software, significantly enhances the utility of the MALDI PharmaPulse 2.0 solution.

10 Diagnostic Imaging Trends for 2018


Digital version